Home / Library / Vitamin D & K

Vitamin D & K

Typical form: Vitamin D3 (Cholecalciferol) + Vitamin K2 (MK-7)

Recommended test

25-Hydroxyvitamin D (25-OH D)

This is typically added case-by-case — when a lab from an outside provider shows low vitamin D — rather than as part of the core panel. In practice, the main draw here is immune function rather than bone health: vitamin D acts as an immune modulator, and low status is linked to higher rates of respiratory infections and several autoimmune conditions. K2 is included alongside it as a balance, directing the calcium D3 helps absorb toward bone rather than arteries.

D3 alone corrects deficiency — for straightforward low vitamin D, standard clinical guidance is cholecalciferol on its own; K2 is added for its separate bone/arterial rationale, not because it's necessary to fix a deficient D level.

Common forms & typical benefits

D3 (Cholecalciferol) + K2 (MK-7)

Vitamin D3 (Cholecalciferol)

The form the body itself produces from sun exposure, and the standard, most-studied supplemental form
Raises calcium absorption from the gut and supports bone, immune, and broad cellular function

Vitamin K2 (MK-7)

Included as a balance to D3 — activates the proteins that direct calcium into bone rather than arterial walls

Research noteA 3-year RCT in 244 postmenopausal women found 180mcg/day MK-7 significantly improved arterial stiffness measures compared to a slight worsening in the placebo group, and halved a biomarker of inactive (non-working) MGP. The same research group's earlier 3-year trial found MK-7 slowed bone loss at the spine and femoral neck, though not at the total hip.

What the research says

Evidence by outcome

Outcome	Approx. evidence base	Typical finding
Acute respiratory infection risk (D3)	Meta-analyses of RCTs	Small protective effect overall, most pronounced in those who are vitamin D deficient and in children
Autoimmune/infection risk (D3, observational)	Meta-analyses of observational studies	Low vitamin D status linked to higher rates of respiratory infections, MS, type 1 diabetes, IBD, and lupus
Autoimmune condition management (D3, RCTs)	Meta-analyses of RCTs	Modest benefit for management of type 1 diabetes and IBD specifically
Fracture risk (D3 alone, large outcome trial)	VITAL trial, 25,871 people	No reduction in fracture risk from D3 supplementation alone
Arterial stiffness (K2, MK-7)	RCT, 244 postmenopausal women, 3 years	Significant improvement vs. placebo; inactive-MGP biomarker halved
Bone density (K2, MK-7)	RCT, postmenopausal women, 3 years	Slowed bone loss at spine and femoral neck; no effect at total hip
Coronary artery calcium progression (high-dose D3+K2)	RCT, 389 people with no prior heart disease, 2 years	No significant slowing of calcium progression overall — a small subgroup showed benefit, but the primary result was neutral

Worth being direct about the strength of each piece here. The immune-function evidence is genuinely the best fit for how this is used in practice — vitamin D's role as an immune modulator is well established mechanistically, and RCTs show a real, if modest, protective effect against respiratory infections, concentrated in people who are actually deficient — which lines up with the seasonal, case-by-case way it's used here. The bone and cardiovascular findings are separate research questions: the largest D3-alone trial (VITAL) did not find a fracture-risk benefit, and K2's bone/arterial evidence, while real, comes from a small number of long trials, with the one hard-outcome coronary calcium trial coming back neutral. Those aren't the primary reason this combination is recommended here, but they're worth knowing.

Research summary chart

View PDF ↗

Dosages used in studies

What the research actually tested

Goal	Typical dose	Notes	Duration
Practitioner-used starting dose (this site)	1,000 IU/day, titrated up as needed	Often using liquid drops for finer titration; rarely exceeds 3,000 IU	Ongoing, retest to guide adjustment
General D3 repletion (VITAL trial)	2,000 IU/day	D3 alone, no K2	Multi-year
Bone/arterial support (K2)	180–200 mcg/day MK-7	The dose behind the positive bone/arterial-stiffness trials	3 years (studied); ongoing in practice
High-dose combination (CAC study)	D3 1,000 IU + K2 720 mcg/day	Notably higher K2 dose than the positive arterial-stiffness trials; still came back neutral on primary outcome	2 years

Safety notes & high-dose risks

What to watch for

Warfarin — a genuine contraindication, not a general caution. Vitamin K2 works against warfarin's mechanism directly (warfarin is a vitamin K antagonist), and can meaningfully alter INR. This combination should not be started for anyone on warfarin without direct coordination with the prescribing provider — some guidance considers it contraindicated outright. This is a sharper interaction than most others in this library, not just a "check with your doctor" footnote.
High-dose vitamin D can also affect warfarin activity independently — a second reason this combination needs direct medical coordination for anyone on anticoagulants.
Hypercalcemia risk above the standard upper limit of 4,000 IU/day (the NIH's tolerable upper intake level for adults), especially when combined with calcium supplementation. Some long-term studies show a small but real uptick in risk starting around 3,200-4,000 IU/day — low absolute risk (~4 extra cases per 1,000 people) and usually asymptomatic, resolving once stopped. True symptomatic toxicity is generally described starting well above that, around 10,000+ IU/day sustained over time.
At standard studied doses, both D3 and K2 (MK-7) have a strong general safety record.

Additional notes

Worth knowing

This one is genuinely case-by-case — added when an outside lab shows low vitamin D, not part of the core structured panel the way Magnesium or Iron are. Seen occasionally, and typically addressed seasonally: used during colder months when sun exposure is low, with a preference for encouraging actual sun exposure over supplementation once exposure picks back up.
K2's role here is simply balance, not a separately dosed/optimized nutrient in its own right — it's included to direct the calcium D3 helps absorb toward bone rather than arteries, not chosen for a specific K2 form strategy beyond that.
Not required to correct simple deficiency: if the only goal is fixing a low vitamin D lab result, D3 alone is the standard, evidence-based approach — K2 is an addition for its separate bone/arterial rationale.
Fat-soluble: both nutrients need a meal containing fat to absorb well.
Retesting: 25-OH vitamin D roughly 8-12 weeks after starting or adjusting dose.

Shop on Fullscript Shop on Prodrome

Educational information only — not medical advice. Lab testing and any supplementation decisions should be made with a qualified healthcare provider who knows your personal health history. Research findings vary by population, dose, form, and study quality.

Some links go to Fullscript, where I may earn a commission at no extra cost to you. I only recommend supplements I've either used myself or seen work in my clients' lab data. Results vary from person to person.